Given that both PDGFRA CNVs and dysregulation of tumor-related pathways are usually present in cancer, we propose that the CN gain of PDGFRA pathway could be a potential target for analyzing cancer-related mechanisms in ACC, KIRC, LUAD, SARC, and UCEC. This evidence concerns the gene PDGFRA and adrenal cortex carcinoma.